
Pulmonary Surface Irregularity score: a Quantitative CT Biomarker for Idiopathic Pulmonary FibrosisAward last edited on: 12/30/2023
Sponsored Program
STTRAwarding Agency
NIH : NIGMSTotal Award Amount
$306,499Award Phase
1Solicitation Topic Code
859Principal Investigator
Robert B JacobusCompany Information
AI Metrics LLC
1500 First Avenue North Suite 101
Birmingham, AL 35203
Birmingham, AL 35203
(205) 573-3332 |
nfo@aimetrics.com |
www.aimetrics.com |
Research Institution
University of Alabama - Birmingham
Phase I
Contract Number: 1R41GM146329-01Start Date: 9/23/2021 Completed: 8/31/2022
Phase I year
2021Phase I Amount
$299,999Project narrative:
Idiopathic pulmonary fibrosis (IPF) is the most common fibrotic lung disease and is a rapidly progressive and fatal disease with limited treatment options due to the lack of an externally validated biomarker to stratify patient phenotype, evaluate longitudinal response to therapy, and serve as a surrogate endpoint in clinical trials and clinical practice. High-resolution computed tomography (CT) is routinely acquired for all patients with IPF and other forms of pulmonary fibrosis, and a CT biomarker that can be applied to existing high-resolution CT images would add no additional patient cost or radiation to the standard of care. We developed a quantitative biomarker to measure pulmonary surface irregularity (PSI) on high-resolution CT images to generate a PSI score in tenths of a millimeter, and the purpose of this proposal is to externally validate the PSI score as a quantitative biomarker for IPF and other causes of pulmonary fibrosis using existing high-resolution CT images and data from the Pulmonary Fibrosis Foundation Patient Registry (N=2003). Age ; ages ; Automation ; Carbon Monoxide ; Cicatrix ; Scars ; Clinical Trials ; Diffusion ; Disease ; Disorder ; Foundations ; indexing ; Lung ; Lung Respiratory System ; pulmonary ; Lung diseases ; Pulmonary Diseases ; Pulmonary Disorder ; Respiratory Disease ; Respiratory System Disease ; Respiratory System Disorder ; disease of the lung ; disorder of the lung ; lung disorder ; Pulmonary function tests ; Lung Function Tests ; Respiratory Function Tests ; Methods ; mortality ; Patient Outcomes Assessments ; Patient Reported Measures ; Patient Reported Outcomes ; Patients ; Phenotype ; Physiology ; Pulmonary Fibrosis ; lung fibrosis ; Research ; Retrospective Studies ; Computer software ; Software ; X-Ray Computed Tomography ; CAT scan ; CT X Ray ; CT Xray ; CT imaging ; CT scan ; Computed Tomography ; Tomodensitometry ; X-Ray CAT Scan ; X-Ray Computerized Tomography ; Xray CAT scan ; Xray Computed Tomography ; Xray computerized tomography ; catscan ; computed axial tomography ; computer tomography ; computerized axial tomography ; computerized tomography ; Transplantation ; transplant ; United States ; Vital capacity ; Forced Vital Capacity ; Gender ; Measures ; Surrogate Markers ; surrogate bio-markers ; surrogate biomarkers ; Data Set ; Dataset ; Surrogate Endpoint ; Surrogate End Points ; base ; lung imaging ; Pulmonary imaging ; lung scanning ; Surface ; Clinical ; prognostic ; Training ; Visual ; Databases ; Data Bases ; data base ; Measurement ; Disease Progression ; Patient Selection ; Phase III Clinical Trials ; Phase 3 Clinical Trials ; phase III protocol ; Therapeutic Agents ; millimeter ; Severities ; Protocol ; Protocols documentation ; System ; cohort ; Speed ; advanced illness ; advanced disease ; Agreement ; Radiation ; response ; drug development ; patient registry ; Institution ; Data ; high resolution CT ; High Resolution Computed Tomography ; Molecular Marker of Prognosis ; Prognosis Marker ; prognostic biomarker ; prognostic indicator ; Prognostic Marker ; Clinical Data ; Validation ; Development ; developmental ; Image ; imaging ; cost ; Outcome ; prospective ; novel therapeutics ; new drug treatments ; new drugs ; new therapeutics ; new therapy ; next generation therapeutics ; novel drug treatments ; novel drugs ; novel therapy ; standard of care ; Biological Markers ; bio-markers ; biologic marker ; biomarker ; clinical practice ; patient stratification ; stratified patient ; primary endpoint ; primary end point ; early phase trial ; idiopathic pulmonary fibrosis ; diffuse interstitial pulmonary fibrosis ; antifibrotic treatment ; antifibrotic therapy ; Prognosis ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00